14种肝细胞癌预测模型在慢性乙型肝炎中的比较性能:治疗中系列时间点的动态验证
基于986例接受恩替卡韦治疗的初治慢性乙型肝炎患者全国前瞻性队列,在第26、52、78和104周使用治疗中数值计算14种肝细胞癌风险评分并评估3年预测性能。中位随访4.7年期间56例(7.5%)发生肝细胞癌,多数模型在前2年治疗中数值下区分度可接受(AUC 0.68至0.81),REAL-B、AASL-HCC、CAMD和mPAGE-B表现较好。
要点
- 前2年治疗中数值下多数模型AUC为0.68至0.81,REACH-B、NGM-HCC和PAGE-B除外。
- REAL-B与CAMD在前2年重新评估时校准良好,Brier评分0.037至0.052。
- REAL-B、AASL-HCC和mPAGE-B可将30%至40%患者归为低风险,低风险组肝细胞癌发生率0.40%至1.56%。
核心结论
- 在接受抗病毒治疗的慢性乙型肝炎队列中,多数肝细胞癌预测模型即使使用前2年治疗中数值也表现良好,尤其是REAL-B、AASL-HCC、CAMD和mPAGE-B模型。
研究设计与样本
- 基于986例接受恩替卡韦治疗的初治慢性乙型肝炎患者全国前瞻性队列,每26周随访一次。
- 分别使用第26、52、78和104周的治疗中数值计算14种肝细胞癌风险评分。
- 采用时间依赖受试者工作特征曲线下面积(AUC)和校准指数评估模型预测3年肝细胞癌的性能。
- 通过常用诊断准确性指标验证模型截断值。
主要发现
- 中位随访4.7年期间,56例(7.5%)发生肝细胞癌。
- 前2年治疗中数值下多数模型区分度可接受,AUC范围为0.68至0.81,但REACH-B、NGM-HCC和PAGE-B除外,且AUC从第26周到第104周略有下降。
- REAL-B、CAMD、GAG-HCC、AASL-HCC、LSM-HCC、mPAGE-B和mREACH-BII区分度最高,在第26、52、78和104周重新评估时AUC分别为0.76至0.81、0.72至0.76、0.70至0.76和0.71至0.74。
- 前2年内重新评估时,REAL-B和CAMD校准良好,Brier评分为0.037至0.052。
- 在报告截断值的9种模型中,使用治疗中数值的REAL-B、AASL-HCC和mPAGE-B可将30%至40%患者识别为低风险,低风险组肝细胞癌发生率极低(0.40%[REAL-B]至1.56%[mPAGE-B])。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To assess comparative performance of 14 hepatocellular carcinoma (HCC) prediction models in chronic hepatitis B (CHB) patients using on-treatment values at different timepoints. METHODS: Based on a nationwide prospective cohort of 986 treatment-naive CHB patients undergoing entecavir therapy with every 26-week follow-up, 14 HCC risk scores were calculated using on-treatment values at week 26, 52, 78, and 104, respectively. Model performance predicting 3-year HCC was assessed using time-dependent area under the receiver operating characteristic curve (AUC) and calibration index. Model cutoffs were validated through common diagnostic accuracy measures. RESULTS: During median 4.7-year follow-up, 56 (7.5%) developed HCC. Discrimination using on-treatment values within first 2 years was generally acceptable for most models (AUCs ranging from 0.68 to 0.81), except for REACH-B, NGM-HCC, and PAGE-B, although AUCs slightly decreased from week 26 to 104. Of these, REAL-B, CAMD, GAG-HCC, AASL-HCC, LSM-HCC, mPAGE-B, and mREACH-BII showed highest discrimination with AUCs ranging from 0.76 to 0.81, 0.72 to 0.76, 0.70 to 0.76, and 0.71 to 0.74 when reassessment at week 26, 52, 78, and 104, respectively. With reassessment within first 2 years, both REAL-B and CAMD calibrated well (Brier score ranging from 0.037 to 0.052). Of 9 models reporting cutoffs, REAL-B, AASL-HCC, and mPAGE-B using on-treatment values could identify 30%-40% of patients as low risk with minimal HCC incidence in the low-risk group (0.40% [REAL-B]-1.56% [mPAGE-B]). DISCUSSION: In this undergoing antiviral treatment CHB cohort, most HCC prediction models performed well even using on-treatment values during first 2 years, particularly REAL-B, AASL-HCC, CAMD, and mPAGE-B model.
引用
- Wu S, Zhou J, Wu X, et al. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints. Am J Gastroenterol. 2022. PMID: 35973147. doi:10.14309/ajg.0000000000001865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。